Results 31 to 40 of about 153,698 (346)

Macrophage regulation of graft-vs-host disease

open access: yesWorld Journal of Clinical Cases, 2020
Hematopoietic stem cell transplantation has become a curative choice of many hematopoietic malignancy, but graft-vs-host disease (GVHD) has limited the survival quality and overall survival of hematopoietic stem cell transplantation. Understanding of the
Yaqun Hong, Bo Wan, Xiao-Fan Li
semanticscholar   +1 more source

A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation

open access: yesHaematologica, 2016
Improvement of graft-versus-host disease prophylaxis remains an important goal in allogeneic hematopoietic stem cell transplantation. Based on reports of possibly preferential properties of sirolimus, we compared the standard regimen of cyclosporine and ...
Johan Törlén   +8 more
doaj   +1 more source

One-way donor-to-recipient human leukocyte antigen mismatch and graft-versus-host disease in liver transplantation: an observational study of a single-center experience in Korea

open access: yesKorean Journal of Transplantation, 2023
Background : Graft-versus-host disease (GVHD) is a rare, but potentially fatal complication of liver transplantation. One-way human leukocyte antigens (HLA) mismatch has emerged as a risk factor for GVHD.
Seung Hyuk Yim   +4 more
doaj   +1 more source

Extracorporeal photopheresis for graft‐vs‐host disease: A literature review and treatment guidelines proposed by the Nordic ECP Quality Group

open access: yesEuropean Journal of Haematology, 2020
Extracorporeal photopheresis (ECP) is one of the most used and established therapies for steroid‐refractory graft‐vs‐host disease (GvHD), with a good effect to side effect profile.
M. Nygaard   +3 more
semanticscholar   +1 more source

Regulation of autoimmunity and donor cell engraftment by recipient Lyt-2+ cells during the graft-versus-host reaction. [PDF]

open access: yes, 1987
When lymphocytes from DBA/2 mice are transferred to (C57BL X DBA/2)F1 (BDF1) mice, the ensuing graft-vs.-host reaction (GVHR) causes an autoimmune illness resembling human SLE.
Harper, SE, Roubinian, JR, Seaman, WE
core   +3 more sources

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. [PDF]

open access: yes, 2019
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival ...
Abdel-Azim, Hisham   +53 more
core   +2 more sources

Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model

open access: yesFrontiers in Immunology, 2019
Mesenchymal stromal cells (MSCs) have potent immunomodulatory properties that make them an attractive tool against graft- vs.-host disease (GVHD).
C. Grégoire   +13 more
semanticscholar   +1 more source

Immunomagnetic t-lymphocyte depletion (ITLD) of rat bone marrow using OX-19 monoclonal antibody [PDF]

open access: yes, 1989
Graft versus host disease (GVHD) may be abrogated and host survival prolonged by in vitro depletion of T lymphocytes from bone marrow (BM) prior to allotransplantation. Using a mouse anti-rat pan T-lymphocyte monoclonal antibody (0×19) bound to monosized,
A. Pascualone   +30 more
core   +1 more source

Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study

open access: yesFrontiers in Immunology, 2018
Patients with steroid refractory gastrointestinal (GI) tract graft- vs.-host disease (GvHD) face a poor prognosis and limited therapeutic options. To accurately assess the efficacy and safety of fecal microbiota transplantation (FMT) in treating steroid ...
X. Qi   +7 more
semanticscholar   +1 more source

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [PDF]

open access: yes, 2017
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival.
Al Mumma   +41 more
core   +1 more source

Home - About - Disclaimer - Privacy